U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Links from BioSample

ERX9768805: Illumina NovaSeq 6000 paired end sequencing; Illumina NovaSeq 6000 paired end sequencing; COG-UK/LSPA-2C4CE6F3/SANG:220920_A01250_0434_AH5CFYDRX2/1t376
1 ILLUMINA (Illumina NovaSeq 6000) run: 1.1M spots, 446M bases, 47.4Mb downloads

Design: Illumina NovaSeq 6000 amplicon sequencing. Samples prepared and sequenced by Donald Fraser, Suki Lee, Rob Howes, The Rosalind Franklin Laboratory and Alex Alderton, Roberto Amato, Jeffrey Barrett, Sonia Goncalves, Ewan Harrison, David K. Jackson, Ian Johnston, Dominic Kwiatkowski, Cordelia Langford, John Sillitoe on behalf of the Wellcome Sanger Institute COVID-19 Surveillance Team
Submitted by: Wellcome Sanger Institute
Study: COVID-19 Genomics UK (COG-UK) consortium
show Abstracthide Abstract
The COVID-19 Genomics UK (COG-UK) – Consortium, which will deliver a large scale and rapid SARS-CoV-2 sequencing capacity to the four UK Public Health Agencies (UK-PHA), local NHS centres and the UK government at pace. The primary achievement of this consortium will be the generation of actionable data which when combined with epidemiological and clinical information has the potential to inform interventions and policy decisions during the current UK COVID-19 epidemic. This sequencing capacity will enable real time evaluation of novel treatments and non-pharmacological interventions on SARS-CoV-2 populations and spread, and provide information on introductions versus community transmission and outbreaks. It will also evaluate signals of changing transmissibility and virulence.In the longer term, the full integration of UK population level SARS-CoV-2 genomics data, with matching NHS electronic health records, patient outcomes, human genomics and metagenomics data has the potential to generate insights into susceptibility to COVID-19 disease. Finally, the substantial new nationwide capacity in sequencing infrastructure, informatics and personnel that will be built by COGUK will remain at the end of the COVID-19 pandemic as a significant asset for the NHS, UK-PHA, UKRI and UK Government.
Sample: COG-UK/LSPA-2C4CE6F3
SAMEA111393297 • ERS13490275 • All experiments • All runs
Library:
Name: NT1772135S / HT-139127:D12
Instrument: Illumina NovaSeq 6000
Strategy: AMPLICON
Source: VIRAL RNA
Selection: PCR
Layout: PAIRED
Experiment attributes:
artic_primer_version: 4.1alt
Runs: 1 run, 1.1M spots, 446M bases, 47.4Mb
Run# of Spots# of BasesSizePublished
ERR102341591,067,930446M47.4Mb2022-09-25

ID:
24598505

Supplemental Content

Recent activity

Your browsing activity is temporarily unavailable.